Nebivolol Hydrochloride Patent Expiration

Nebivolol Hydrochloride is Used for treating high blood pressure. It was first introduced by Allergan Sales Llc in its drug Bystolic on Dec 17, 2007. 19 different companies have introduced drugs containing Nebivolol Hydrochloride.


Nebivolol Hydrochloride Patents

Given below is the list of patents protecting Nebivolol Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Bystolic US6545040 Method of lowering the blood pressure Dec 17, 2021

(Expired)

Allergan
Bystolic US5759580 Compositions containing micronized nebivolol Jun 02, 2015

(Expired)

Allergan



Nebivolol Hydrochloride's Family Patents

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List

Nebivolol Hydrochloride Generic API Manufacturers

Several generic applications have been filed for Nebivolol Hydrochloride. The first generic version for Nebivolol Hydrochloride was by Ani Pharmaceuticals Inc and was approved on Apr 16, 2015. And the latest generic version is by Macleods Pharmaceuticals Ltd and was approved on Jan 28, 2025.

Given below is the list of companies who have filed for Nebivolol Hydrochloride generic, along with the locations of their manufacturing plants worldwide.